Period:
Draw Mode:
| Volume | 232,935 |
|
|||||
| News | - | ||||||
| Day High | 2.69 | Low High |
|||||
| Day Low | 2.57 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Assertio Holdings Inc | ASRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 2.33% | 2.64 | 10:22:30 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.58 | 2.57 | 2.69 | 2.58 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,364 | 232,935 | $ 2.64 | $ 615,793 | - | 2.0747 - 8.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:23:06 | 1 | $ 2.631 | USD |
Assertio Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 149.2M | 56.52M | - | 156.23M | 109.63M | 1.94 | 1.36 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Assertio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ASRT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.62 | 2.70 | 2.50 | 2.59 | 1,438,585 | 0.02 | 0.76% |
| 1 Month | 3.28 | 3.40 | 2.50 | 2.95 | 1,928,907 | -0.64 | -19.51% |
| 3 Months | 5.55 | 5.78 | 2.50 | 3.77 | 2,300,892 | -2.91 | -52.43% |
| 6 Months | 6.02 | 8.01 | 2.50 | 4.99 | 2,164,023 | -3.38 | -56.15% |
| 1 Year | 2.09 | 8.01 | 2.0747 | 4.84 | 1,757,823 | 0.55 | 26.32% |
| 3 Years | 0.68 | 8.01 | 0.33 | 1.82 | 2,983,683 | 1.96 | 288.24% |
| 5 Years | 5.95 | 8.01 | 0.33 | 1.83 | 2,275,341 | -3.31 | -55.63% |
Assertio Description
| Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |